Kristen Nowak
Concepts (314)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Polycystic Kidney, Autosomal Dominant | 23 | 2026 | 235 | 10.020 |
Why?
| | Renal Insufficiency, Chronic | 28 | 2025 | 653 | 5.950 |
Why?
| | Vascular Stiffness | 15 | 2026 | 486 | 3.760 |
Why?
| | Endothelium, Vascular | 17 | 2025 | 965 | 2.510 |
Why?
| | Glomerular Filtration Rate | 14 | 2026 | 760 | 2.100 |
Why?
| | Kidney | 14 | 2026 | 1495 | 2.070 |
Why?
| | Blood Pressure | 15 | 2026 | 1769 | 2.040 |
Why?
| | Kidney Failure, Chronic | 9 | 2020 | 598 | 1.730 |
Why?
| | Caloric Restriction | 3 | 2024 | 127 | 1.500 |
Why?
| | Sodium, Dietary | 3 | 2023 | 37 | 1.490 |
Why?
| | Cognitive Dysfunction | 4 | 2025 | 461 | 1.460 |
Why?
| | Blood Vessels | 4 | 2024 | 171 | 1.340 |
Why?
| | Vascular Diseases | 4 | 2021 | 251 | 1.330 |
Why?
| | Dementia | 2 | 2025 | 303 | 1.270 |
Why?
| | Hypertension | 7 | 2021 | 1263 | 1.260 |
Why?
| | Sodium | 3 | 2019 | 197 | 1.250 |
Why?
| | Overweight | 3 | 2026 | 609 | 1.230 |
Why?
| | Diet, Sodium-Restricted | 4 | 2020 | 38 | 1.160 |
Why?
| | Inflammation | 9 | 2025 | 2878 | 1.120 |
Why?
| | Disease Progression | 11 | 2026 | 2847 | 1.100 |
Why?
| | Cardiovascular Diseases | 14 | 2026 | 2168 | 1.100 |
Why?
| | Brachial Artery | 10 | 2025 | 206 | 1.040 |
Why?
| | Oxidative Stress | 14 | 2026 | 1339 | 1.010 |
Why?
| | Renal Circulation | 2 | 2026 | 75 | 0.990 |
Why?
| | Pulse Wave Analysis | 11 | 2026 | 266 | 0.900 |
Why?
| | Interleukin-1 | 3 | 2019 | 961 | 0.880 |
Why?
| | Renal Dialysis | 5 | 2019 | 462 | 0.850 |
Why?
| | Obesity | 3 | 2026 | 3077 | 0.840 |
Why?
| | Lipocalin-2 | 2 | 2024 | 79 | 0.830 |
Why?
| | Recombinant Fusion Proteins | 2 | 2017 | 675 | 0.830 |
Why?
| | Cognition | 4 | 2025 | 1266 | 0.830 |
Why?
| | Kidney Tubules | 1 | 2024 | 117 | 0.800 |
Why?
| | Middle Aged | 46 | 2026 | 35875 | 0.790 |
Why?
| | Metformin | 2 | 2024 | 318 | 0.780 |
Why?
| | Intra-Abdominal Fat | 1 | 2024 | 100 | 0.780 |
Why?
| | Humans | 84 | 2026 | 144759 | 0.760 |
Why?
| | Vasodilation | 8 | 2025 | 523 | 0.740 |
Why?
| | Aging | 8 | 2018 | 1966 | 0.730 |
Why?
| | Male | 59 | 2026 | 72315 | 0.720 |
Why?
| | Fibroblast Growth Factors | 3 | 2019 | 188 | 0.700 |
Why?
| | Curcumin | 1 | 2021 | 25 | 0.700 |
Why?
| | Double-Blind Method | 13 | 2025 | 2029 | 0.690 |
Why?
| | Aged | 34 | 2025 | 25913 | 0.680 |
Why?
| | Chronic Kidney Disease-Mineral and Bone Disorder | 2 | 2018 | 14 | 0.670 |
Why?
| | Endothelial Cells | 4 | 2023 | 869 | 0.650 |
Why?
| | Female | 55 | 2026 | 78271 | 0.650 |
Why?
| | Biomarkers | 9 | 2025 | 4271 | 0.640 |
Why?
| | Renal Agents | 1 | 2020 | 5 | 0.630 |
Why?
| | Systole | 1 | 2020 | 178 | 0.630 |
Why?
| | Polycystic Kidney Diseases | 1 | 2019 | 71 | 0.580 |
Why?
| | Spironolactone | 1 | 2019 | 39 | 0.570 |
Why?
| | Kidney Neoplasms | 1 | 2023 | 412 | 0.570 |
Why?
| | Mineralocorticoid Receptor Antagonists | 1 | 2019 | 68 | 0.550 |
Why?
| | Potassium, Dietary | 1 | 2018 | 12 | 0.540 |
Why?
| | Drinking Water | 1 | 2019 | 97 | 0.530 |
Why?
| | Hyponatremia | 1 | 2018 | 43 | 0.530 |
Why?
| | Healthy Lifestyle | 1 | 2018 | 37 | 0.530 |
Why?
| | Interleukin-6 | 2 | 2020 | 780 | 0.520 |
Why?
| | Autophagy | 1 | 2019 | 286 | 0.510 |
Why?
| | Death | 1 | 2018 | 130 | 0.510 |
Why?
| | Primary Prevention | 2 | 2018 | 220 | 0.510 |
Why?
| | Adult | 29 | 2026 | 40449 | 0.490 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 3 | 2025 | 439 | 0.460 |
Why?
| | Cerebrovascular Circulation | 3 | 2025 | 280 | 0.460 |
Why?
| | Vitamin D | 5 | 2018 | 400 | 0.450 |
Why?
| | Atherosclerosis | 2 | 2018 | 409 | 0.440 |
Why?
| | Energy Metabolism | 2 | 2024 | 935 | 0.440 |
Why?
| | Cross-Sectional Studies | 7 | 2026 | 5868 | 0.430 |
Why?
| | Bacterial Infections | 1 | 2016 | 246 | 0.430 |
Why?
| | Sodium Bicarbonate | 3 | 2025 | 47 | 0.410 |
Why?
| | Hypercapnia | 2 | 2023 | 54 | 0.380 |
Why?
| | Longitudinal Studies | 5 | 2018 | 2947 | 0.380 |
Why?
| | Hepatitis A Virus Cellular Receptor 1 | 2 | 2024 | 41 | 0.370 |
Why?
| | Sodium Chloride, Dietary | 2 | 2023 | 31 | 0.340 |
Why?
| | Risk Factors | 11 | 2025 | 10779 | 0.340 |
Why?
| | Acidosis | 2 | 2025 | 105 | 0.340 |
Why?
| | Apoptosis | 1 | 2019 | 2430 | 0.340 |
Why?
| | Carotid Arteries | 3 | 2018 | 207 | 0.330 |
Why?
| | Time Factors | 7 | 2021 | 7173 | 0.310 |
Why?
| | Body Mass Index | 3 | 2026 | 2438 | 0.310 |
Why?
| | Sex Factors | 4 | 2025 | 2112 | 0.310 |
Why?
| | Vascular Calcification | 2 | 2018 | 110 | 0.310 |
Why?
| | Regional Blood Flow | 7 | 2016 | 514 | 0.310 |
Why?
| | Young Adult | 12 | 2024 | 14105 | 0.300 |
Why?
| | Cardiovascular System | 2 | 2023 | 137 | 0.300 |
Why?
| | Uric Acid | 2 | 2018 | 166 | 0.290 |
Why?
| | Organ Size | 3 | 2025 | 463 | 0.290 |
Why?
| | Prospective Studies | 10 | 2025 | 7990 | 0.290 |
Why?
| | TRPP Cation Channels | 2 | 2020 | 74 | 0.290 |
Why?
| | Pravastatin | 2 | 2025 | 43 | 0.280 |
Why?
| | NF-kappa B | 4 | 2015 | 661 | 0.260 |
Why?
| | Aorta | 3 | 2026 | 429 | 0.260 |
Why?
| | Cohort Studies | 5 | 2024 | 5960 | 0.250 |
Why?
| | Energy Intake | 2 | 2020 | 499 | 0.250 |
Why?
| | Independent Living | 2 | 2018 | 114 | 0.250 |
Why?
| | Femoral Artery | 2 | 2018 | 190 | 0.250 |
Why?
| | Postmenopause | 2 | 2026 | 391 | 0.250 |
Why?
| | Phosphates | 2 | 2024 | 180 | 0.240 |
Why?
| | Hospitalization | 1 | 2016 | 2433 | 0.240 |
Why?
| | Brain | 1 | 2018 | 2933 | 0.220 |
Why?
| | Angiotensin Receptor Antagonists | 1 | 2015 | 114 | 0.220 |
Why?
| | Kaplan-Meier Estimate | 2 | 2018 | 965 | 0.210 |
Why?
| | Chitinase-3-Like Protein 1 | 1 | 2024 | 18 | 0.210 |
Why?
| | Angiotensin-Converting Enzyme Inhibitors | 1 | 2015 | 221 | 0.210 |
Why?
| | Lanthanum | 1 | 2024 | 13 | 0.210 |
Why?
| | Antidiuretic Hormone Receptor Antagonists | 1 | 2024 | 10 | 0.210 |
Why?
| | Transcription Factor CHOP | 1 | 2014 | 32 | 0.210 |
Why?
| | Neonatal Screening | 1 | 2026 | 178 | 0.210 |
Why?
| | Potassium | 1 | 2014 | 152 | 0.210 |
Why?
| | Genotype | 2 | 2020 | 1833 | 0.210 |
Why?
| | Exercise | 4 | 2018 | 2201 | 0.210 |
Why?
| | Inflammasomes | 1 | 2025 | 146 | 0.210 |
Why?
| | Physical Fitness | 2 | 2013 | 209 | 0.210 |
Why?
| | Chemokine CCL2 | 1 | 2024 | 115 | 0.210 |
Why?
| | Blood Flow Velocity | 2 | 2023 | 413 | 0.200 |
Why?
| | Fatty Acid-Binding Proteins | 1 | 2024 | 79 | 0.200 |
Why?
| | Obesity, Abdominal | 1 | 2024 | 46 | 0.200 |
Why?
| | Minerals | 2 | 2019 | 47 | 0.200 |
Why?
| | Bufanolides | 1 | 2013 | 4 | 0.200 |
Why?
| | Diet, Ketogenic | 1 | 2023 | 37 | 0.200 |
Why?
| | Magnetic Resonance Imaging | 3 | 2024 | 3863 | 0.200 |
Why?
| | Glycosphingolipids | 1 | 2023 | 7 | 0.200 |
Why?
| | Pneumonia, Bacterial | 1 | 2014 | 113 | 0.190 |
Why?
| | Cystatin C | 1 | 2013 | 65 | 0.190 |
Why?
| | Pilot Projects | 6 | 2025 | 1886 | 0.190 |
Why?
| | Genetic Testing | 1 | 2026 | 478 | 0.190 |
Why?
| | Inflammation Mediators | 3 | 2025 | 509 | 0.190 |
Why?
| | Treatment Outcome | 7 | 2025 | 11679 | 0.180 |
Why?
| | Reactive Oxygen Species | 2 | 2023 | 621 | 0.180 |
Why?
| | Calcinosis | 1 | 2014 | 234 | 0.180 |
Why?
| | Community-Acquired Infections | 1 | 2014 | 174 | 0.180 |
Why?
| | Endoplasmic Reticulum | 1 | 2014 | 266 | 0.180 |
Why?
| | Blood Glucose | 2 | 2021 | 2327 | 0.180 |
Why?
| | Randomized Controlled Trials as Topic | 4 | 2023 | 1720 | 0.180 |
Why?
| | Patients | 1 | 2023 | 180 | 0.170 |
Why?
| | Adolescent | 7 | 2021 | 22428 | 0.170 |
Why?
| | Informed Consent | 1 | 2023 | 198 | 0.170 |
Why?
| | Forearm | 2 | 2009 | 140 | 0.170 |
Why?
| | Kidney Diseases | 1 | 2025 | 427 | 0.170 |
Why?
| | Creatinine | 1 | 2013 | 506 | 0.170 |
Why?
| | Case-Control Studies | 4 | 2025 | 3604 | 0.160 |
Why?
| | Genomics | 1 | 2026 | 834 | 0.160 |
Why?
| | Endothelin-1 | 2 | 2009 | 184 | 0.160 |
Why?
| | Parathyroid Hormone | 2 | 2018 | 112 | 0.160 |
Why?
| | Cytokines | 2 | 2018 | 2061 | 0.160 |
Why?
| | Allopurinol | 2 | 2018 | 69 | 0.160 |
Why?
| | Salicylates | 2 | 2015 | 29 | 0.160 |
Why?
| | Euthyroid Sick Syndromes | 1 | 2020 | 6 | 0.160 |
Why?
| | Follow-Up Studies | 3 | 2019 | 5408 | 0.160 |
Why?
| | Nutritive Value | 1 | 2020 | 38 | 0.160 |
Why?
| | C-Reactive Protein | 2 | 2018 | 416 | 0.150 |
Why?
| | Caspase Inhibitors | 1 | 2019 | 81 | 0.150 |
Why?
| | Child | 5 | 2023 | 22633 | 0.150 |
Why?
| | Salinity | 1 | 2019 | 20 | 0.150 |
Why?
| | Bangladesh | 1 | 2019 | 62 | 0.150 |
Why?
| | Weight Loss | 1 | 2015 | 836 | 0.150 |
Why?
| | Drinking | 1 | 2019 | 42 | 0.150 |
Why?
| | Adiposity | 1 | 2024 | 543 | 0.150 |
Why?
| | Animals | 7 | 2026 | 38058 | 0.150 |
Why?
| | Retrospective Studies | 4 | 2024 | 17066 | 0.150 |
Why?
| | Patient Advocacy | 1 | 2019 | 73 | 0.140 |
Why?
| | Caspases | 1 | 2019 | 232 | 0.140 |
Why?
| | Lipoproteins, HDL | 1 | 2019 | 101 | 0.140 |
Why?
| | Vitamin D Deficiency | 1 | 2010 | 186 | 0.140 |
Why?
| | Carotid Intima-Media Thickness | 1 | 2018 | 75 | 0.140 |
Why?
| | Nitric Oxide Synthase Type III | 1 | 2009 | 204 | 0.140 |
Why?
| | Aryl Hydrocarbon Hydroxylases | 1 | 2008 | 45 | 0.140 |
Why?
| | I-kappa B Proteins | 1 | 2008 | 74 | 0.140 |
Why?
| | Practice Guidelines as Topic | 1 | 2026 | 1560 | 0.140 |
Why?
| | Cross-Over Studies | 4 | 2018 | 601 | 0.130 |
Why?
| | Sepsis | 1 | 2014 | 640 | 0.130 |
Why?
| | Diet | 1 | 2025 | 1273 | 0.130 |
Why?
| | Fathers | 1 | 2018 | 51 | 0.130 |
Why?
| | Free Radical Scavengers | 1 | 2007 | 82 | 0.130 |
Why?
| | Enteral Nutrition | 1 | 2020 | 216 | 0.130 |
Why?
| | Healthy Aging | 1 | 2018 | 40 | 0.130 |
Why?
| | Dietary Supplements | 2 | 2017 | 576 | 0.130 |
Why?
| | Pain | 1 | 2023 | 779 | 0.130 |
Why?
| | Calcitriol | 1 | 2017 | 58 | 0.130 |
Why?
| | Cholecalciferol | 1 | 2017 | 60 | 0.130 |
Why?
| | Health Status | 1 | 2012 | 836 | 0.120 |
Why?
| | Enzyme Inhibitors | 2 | 2016 | 824 | 0.120 |
Why?
| | Hyperuricemia | 1 | 2016 | 47 | 0.120 |
Why?
| | Immunity, Humoral | 1 | 2017 | 120 | 0.120 |
Why?
| | Vasoconstriction | 1 | 2007 | 217 | 0.120 |
Why?
| | Ascorbic Acid | 1 | 2007 | 180 | 0.120 |
Why?
| | Critical Illness | 2 | 2020 | 891 | 0.120 |
Why?
| | Up-Regulation | 1 | 2019 | 851 | 0.120 |
Why?
| | Chronic Disease | 2 | 2019 | 1813 | 0.120 |
Why?
| | Leg | 1 | 2007 | 239 | 0.120 |
Why?
| | Severity of Illness Index | 3 | 2018 | 2925 | 0.110 |
Why?
| | Immunity, Cellular | 1 | 2017 | 272 | 0.110 |
Why?
| | Program Development | 1 | 2018 | 370 | 0.110 |
Why?
| | Neuroimaging | 1 | 2018 | 289 | 0.110 |
Why?
| | Signal Transduction | 2 | 2019 | 5226 | 0.110 |
Why?
| | Intensive Care Units | 1 | 2021 | 916 | 0.110 |
Why?
| | Dose-Response Relationship, Drug | 4 | 2012 | 2027 | 0.110 |
Why?
| | Nutritional Status | 1 | 2018 | 354 | 0.110 |
Why?
| | Cell Nucleus | 1 | 2008 | 618 | 0.110 |
Why?
| | Communicable Diseases | 1 | 2017 | 163 | 0.110 |
Why?
| | Risk Assessment | 3 | 2021 | 3671 | 0.110 |
Why?
| | Family | 1 | 2019 | 679 | 0.110 |
Why?
| | Prenatal Diagnosis | 1 | 2016 | 195 | 0.110 |
Why?
| | Age of Onset | 1 | 2016 | 551 | 0.110 |
Why?
| | Peripheral Arterial Disease | 1 | 2021 | 503 | 0.110 |
Why?
| | Hypoglycemic Agents | 1 | 2024 | 1387 | 0.110 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2020 | 985 | 0.110 |
Why?
| | Myocardial Infarction | 1 | 2022 | 1209 | 0.100 |
Why?
| | Australia | 2 | 2026 | 286 | 0.100 |
Why?
| | Patient Care Team | 1 | 2019 | 689 | 0.100 |
Why?
| | United States | 3 | 2026 | 15966 | 0.100 |
Why?
| | Acute Kidney Injury | 1 | 2021 | 865 | 0.100 |
Why?
| | Program Evaluation | 1 | 2018 | 948 | 0.100 |
Why?
| | Antibodies, Monoclonal | 1 | 2020 | 1519 | 0.100 |
Why?
| | Survival Rate | 1 | 2018 | 2089 | 0.100 |
Why?
| | Prognosis | 2 | 2021 | 4282 | 0.100 |
Why?
| | Aged, 80 and over | 3 | 2025 | 8265 | 0.100 |
Why?
| | Age Factors | 4 | 2025 | 3333 | 0.100 |
Why?
| | Neuropsychological Tests | 1 | 2018 | 1134 | 0.090 |
Why?
| | Communication | 1 | 2019 | 965 | 0.090 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2015 | 338 | 0.090 |
Why?
| | NADPH Oxidases | 2 | 2013 | 124 | 0.090 |
Why?
| | Drug Therapy, Combination | 2 | 2015 | 1047 | 0.090 |
Why?
| | Mothers | 1 | 2018 | 775 | 0.090 |
Why?
| | Fasting | 2 | 2023 | 277 | 0.090 |
Why?
| | Prevalence | 1 | 2018 | 2834 | 0.080 |
Why?
| | Physicians | 1 | 2019 | 939 | 0.080 |
Why?
| | Infant, Newborn | 2 | 2026 | 6429 | 0.080 |
Why?
| | Quality of Life | 1 | 2012 | 3185 | 0.080 |
Why?
| | Lipoproteins, LDL | 2 | 2012 | 119 | 0.070 |
Why?
| | Mutation | 1 | 2020 | 4089 | 0.070 |
Why?
| | Vascular Resistance | 2 | 2012 | 367 | 0.070 |
Why?
| | Vasodilator Agents | 2 | 2009 | 331 | 0.060 |
Why?
| | Middle Cerebral Artery | 1 | 2025 | 56 | 0.060 |
Why?
| | Ultrasonography, Doppler, Transcranial | 1 | 2025 | 48 | 0.060 |
Why?
| | Nitric Oxide | 2 | 2011 | 897 | 0.050 |
Why?
| | Whole Genome Sequencing | 1 | 2026 | 182 | 0.050 |
Why?
| | Ketocholesterols | 1 | 2014 | 8 | 0.050 |
Why?
| | Ezetimibe | 1 | 2014 | 24 | 0.050 |
Why?
| | Vegetables | 1 | 2025 | 170 | 0.050 |
Why?
| | Dilatation, Pathologic | 1 | 2014 | 62 | 0.050 |
Why?
| | Azetidines | 1 | 2014 | 45 | 0.050 |
Why?
| | Simvastatin | 1 | 2014 | 60 | 0.050 |
Why?
| | Apolipoproteins E | 1 | 2014 | 94 | 0.050 |
Why?
| | Mice, Inbred C57BL | 2 | 2026 | 5992 | 0.050 |
Why?
| | Human Umbilical Vein Endothelial Cells | 1 | 2014 | 108 | 0.050 |
Why?
| | Magnetic Resonance Angiography | 1 | 2025 | 251 | 0.050 |
Why?
| | Bicarbonates | 1 | 2023 | 45 | 0.050 |
Why?
| | Cysts | 1 | 2024 | 111 | 0.050 |
Why?
| | Biological Availability | 1 | 2012 | 142 | 0.050 |
Why?
| | Compliance | 1 | 2012 | 49 | 0.050 |
Why?
| | Microcirculation | 1 | 2012 | 138 | 0.050 |
Why?
| | Infant | 1 | 2016 | 10034 | 0.040 |
Why?
| | Disease Management | 1 | 2026 | 645 | 0.040 |
Why?
| | Nutrition Surveys | 1 | 2023 | 282 | 0.040 |
Why?
| | Global Health | 1 | 2025 | 401 | 0.040 |
Why?
| | Meta-Analysis as Topic | 1 | 2012 | 174 | 0.040 |
Why?
| | Odds Ratio | 1 | 2014 | 1075 | 0.040 |
Why?
| | Gonadal Steroid Hormones | 1 | 2022 | 144 | 0.040 |
Why?
| | Leukocyte Count | 1 | 2022 | 316 | 0.040 |
Why?
| | Nitroglycerin | 1 | 2010 | 14 | 0.040 |
Why?
| | 25-Hydroxyvitamin D3 1-alpha-Hydroxylase | 1 | 2010 | 18 | 0.040 |
Why?
| | Receptors, Calcitriol | 1 | 2010 | 55 | 0.040 |
Why?
| | Muscles | 1 | 2021 | 333 | 0.040 |
Why?
| | Colorado | 2 | 2017 | 4564 | 0.040 |
Why?
| | Cholesterol, LDL | 1 | 2012 | 358 | 0.040 |
Why?
| | Triiodothyronine, Reverse | 1 | 2020 | 2 | 0.040 |
Why?
| | Triiodothyronine | 1 | 2020 | 54 | 0.040 |
Why?
| | Lymphocytes | 1 | 2022 | 382 | 0.040 |
Why?
| | Superoxide Dismutase | 1 | 2012 | 301 | 0.040 |
Why?
| | Prediabetic State | 1 | 2013 | 245 | 0.040 |
Why?
| | Thyroxine | 1 | 2020 | 64 | 0.040 |
Why?
| | Chicago | 1 | 2019 | 61 | 0.040 |
Why?
| | Thyrotropin | 1 | 2020 | 118 | 0.040 |
Why?
| | Diet Records | 1 | 2009 | 85 | 0.040 |
Why?
| | Receptor, Endothelin A | 1 | 2009 | 63 | 0.040 |
Why?
| | Lipids | 1 | 2014 | 710 | 0.040 |
Why?
| | Monocytes | 1 | 2022 | 538 | 0.040 |
Why?
| | Logistic Models | 1 | 2014 | 2117 | 0.040 |
Why?
| | Sulfaphenazole | 1 | 2008 | 3 | 0.040 |
Why?
| | NF-KappaB Inhibitor alpha | 1 | 2008 | 49 | 0.040 |
Why?
| | Cytochrome P-450 CYP2C9 | 1 | 2008 | 19 | 0.040 |
Why?
| | omega-N-Methylarginine | 1 | 2008 | 29 | 0.040 |
Why?
| | Testosterone | 1 | 2022 | 419 | 0.040 |
Why?
| | Nitroprusside | 1 | 2008 | 72 | 0.040 |
Why?
| | Professional-Family Relations | 1 | 2019 | 153 | 0.030 |
Why?
| | NLR Family, Pyrin Domain-Containing 3 Protein | 1 | 2019 | 169 | 0.030 |
Why?
| | Ultrasonography, Doppler, Duplex | 1 | 2007 | 40 | 0.030 |
Why?
| | Sex Characteristics | 1 | 2023 | 790 | 0.030 |
Why?
| | Acetylcholine | 1 | 2008 | 204 | 0.030 |
Why?
| | Nitric Oxide Synthase | 1 | 2008 | 235 | 0.030 |
Why?
| | Calcium | 1 | 2013 | 1183 | 0.030 |
Why?
| | Arteries | 1 | 2009 | 259 | 0.030 |
Why?
| | Regression Analysis | 1 | 2020 | 1003 | 0.030 |
Why?
| | Cholesterol | 1 | 2019 | 406 | 0.030 |
Why?
| | Mice, Knockout | 1 | 2014 | 3121 | 0.030 |
Why?
| | Vasoconstrictor Agents | 1 | 2007 | 144 | 0.030 |
Why?
| | Databases, Factual | 1 | 2013 | 1486 | 0.030 |
Why?
| | Epinephrine | 1 | 2007 | 155 | 0.030 |
Why?
| | Norepinephrine | 1 | 2007 | 196 | 0.030 |
Why?
| | Feasibility Studies | 1 | 2021 | 1095 | 0.030 |
Why?
| | Infusions, Intravenous | 1 | 2007 | 423 | 0.030 |
Why?
| | Reference Values | 1 | 2007 | 797 | 0.030 |
Why?
| | Mice | 2 | 2026 | 18339 | 0.030 |
Why?
| | Phosphorylation | 1 | 2009 | 1732 | 0.030 |
Why?
| | Respiration, Artificial | 1 | 2020 | 708 | 0.030 |
Why?
| | Incidence | 1 | 2021 | 2879 | 0.030 |
Why?
| | Acute Disease | 1 | 2017 | 1030 | 0.030 |
Why?
| | Predictive Value of Tests | 1 | 2019 | 2115 | 0.020 |
Why?
| | Recovery of Function | 1 | 2017 | 707 | 0.020 |
Why?
| | Decision Making | 1 | 2019 | 975 | 0.020 |
Why?
| | Insulin | 1 | 2013 | 2507 | 0.020 |
Why?
| | Heart Rate | 1 | 2015 | 855 | 0.020 |
Why?
| | Surveys and Questionnaires | 1 | 2023 | 6048 | 0.020 |
Why?
|
|
Nowak's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|